Showing results (71-80 of 84) with videos related to
Sort By:
Pageof 9
Journal of Medicinal Chemistry|November 15, 2021
Active Learning for Drug Design: A Case Study on the Plasma Exposure of Orally Administered DrugsXiaoyu Ding, Rongrong Cui, Jie Yu, et al.ACS Applied Materials & Interfaces|April 19, 2018
Systematic Study in Mammalian Cells Showing No Adverse Response to Tetrahedral DNA NanostructureKai Xia, Huating Kong, Yunzhi Cui, et al.Journal of Medicinal Chemistry|January 10, 2024
Design, Synthesis, and Biological Evaluation of Potent and Selective PROTAC Degraders of Oncogenic KRAS<sup>G12D</sup>Chuan Zhou, Zisheng Fan, Yuejiao Gu, et al.Journal of Neurosurgery|December 3, 2021
High-resolution magnetic resonance vessel wall imaging-guided endovascular recanalization for nonacute intracranial artery occlusionZhikai Hou, Long Yan, Zhe Zhang, et al.Acta Pharmaceutica Sinica. B|March 29, 2021
Design, synthesis and biological evaluation of pyrazolo[3,4-<i>d</i>]pyridazinone derivatives as covalent FGFR inhibitorsXiaowei Wu, Mengdi Dai, Rongrong Cui, et al.Journal of Medicinal Chemistry|March 10, 2023
Discovery of a Potent, Cooperative, and Selective SOS1 PROTAC ZZ151 with In Vivo Antitumor Efficacy in KRAS-Mutant CancersZehui Zhou, Guizhen Zhou, Chuan Zhou, et al.Journal of Medicinal Chemistry|November 25, 2021
Discovery of Pyrazolo[3,4-<i>d</i>]pyridazinone Derivatives as Selective DDR1 Inhibitors via Deep Learning Based Design, Synthesis, and Biological EvaluationXiaoqin Tan, Chunpu Li, Ruirui Yang, et al.Journal of Medicinal Chemistry|May 9, 2025
Discovery of 3-(Fluoro-imidazolyl)pyridazine Derivatives as Potent STING Agonists with Antitumor ActivityHui Hou, Jingyi Zhou, Qibang Sui, et al.Journal of Medicinal Chemistry|February 22, 2023
Design, Synthesis, and Biological Evaluation of Bipyridazine Derivatives as Stimulator of Interferon Genes (STING) Receptor AgonistsBin Shan, Hui Hou, Keke Zhang, et al.Journal of Medicinal Chemistry|July 24, 2019
Discovery and Development of a Series of Pyrazolo[3,4-<i>d</i>]pyridazinone Compounds as the Novel Covalent Fibroblast Growth Factor Receptor Inhibitors by the Rational Drug DesignYulan Wang, Yang Dai, Xiaowei Wu, et al.Pageof 9